Molecular Imaging News and Research

RSS

Seven-day event focuses on nuclear medicine, molecular imaging, nanomedicine and clinical trials

SNM will hold its Conjoint Mid-Winter Meetings Jan. 27-Feb. 2, 2010, at the Albuquerque Convention Center in Albuquerque, N.M. This year, SNM joins its annual Mid-Winter Educational Symposium with the 2010 Annual Meeting and Educational Symposium of the American College of Nuclear Medicine (ACNM), the Nanomedicine and Molecular Imaging Summit and the Clinical Trials Network Community Workshop.

25 Nov 2009

Innovation Award for GMI presented at the 2009 World Congress on Medical Physics

Gamma Medica-Ideas, Inc., a leading developer of digital molecular imaging systems, announced today that it has been awarded an Innovation Award for its new prototype imaging system that combines the molecular imaging (MI) capability of single-photon nuclear imaging with magnetic resonance imaging (MRI). The award was presented to GMI at the 2009 World Congress on Medical Physics and Biomedical Engineering in Munich, Germany that took place on September 7th, 2009.

24 Nov 2009

Medical students and biomedical scientists to attend 8th World Congress on Trauma, Shock, Inflammation and Sepsis

The 8th World Congress on Trauma, Shock, Inflammation and Sepsis – TSIS 2010 – will take place from March 9th to13th 2010 in the Auditorium Tract of the Ludwig-Maximilians-University, Campus Grosshadern, in Munich/Germany.

23 Nov 2009

Researchers develop new device with nano-sized features to grab cancer cells

Just as fly paper captures insects, an innovative new device with nano-sized features developed by researchers at UCLA is able to grab cancer cells in the blood that have broken off from a tumor.

19 Nov 2009

ART Advanced Research Technologies receives delisting notice from TSX

ART Advanced Research Technologies Inc., a Canadian medical device company and a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, today announced that it will delay the release of its financial results for the third quarter ended September 30, 2009, considering the restructuring process that the company is currently undergoing.

16 Nov 2009

Changes in CMS reimbursement to accelerate demand for cardiac PET imaging

Positron Corporation a molecular imaging solutions company focused on Nuclear Cardiology, expects the evolution from cardiac SPECT to cardiac PET imaging will be greatly accelerated with the recent changes in reimbursement from the Centers for Medicare & Medicaid Services (CMS) set for 2010.

13 Nov 2009

CMS approves FDG PET for initial staging of cervical cancer

SNM applauds the Centers for Medicare & Medicaid Services- (CMS) decision to expand coverage of FDG PET for the initial staging of cervical cancer without previously imposed restrictions.

13 Nov 2009

Caliper Life Sciences announces financial results for third quarter ended September 30, 2009

Caliper Life Sciences, Inc. today reported results for its third quarter ended September 30, 2009. GAAP revenues increased by 4% to $32.2 million, from non-GAAP revenues of $31.0 million in the same period of 2008, which represents GAAP revenue of $34.0 million in the third quarter of 2008 reduced by $3.0 million for the impact of divested product lines.

9 Nov 2009

PET scanning emerges as an important tool in the evaluation of lung cancer

A rapid decline in metabolic activity on a PET scan after radiation therapy for non-small cell lung cancer is correlated with good local tumor control, according to a study presented by researchers at Thomas Jefferson University Hospital at the 51st ASTRO Annual Meeting.

7 Nov 2009

ART Advanced Research Technologies to secure $1.2M interim financing

ART Advanced Research Technologies Inc., a Canadian medical device company and a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, announced that earlier today it filed a notice of intention to make a proposal to its creditors under the Bankruptcy and Insolvency Act with KPMG Inc. in order to provide the company with the liquidity it requires to pursue its solicitation process.

2 Nov 2009

Molecular imaging pinpoints inflammation in the brains of schizophrenics and migraine sufferers

Inflammatory response of brain cells-as indicated by a molecular imaging technique-could tell researchers more about why certain neurologic disorders, such as migraine headaches and psychosis in schizophrenic patients, occur and provide insight into how to best treat them, according to two studies published in the November issue of the Journal of Nuclear Medicine.

31 Oct 2009

Researchers report preclinical results of a novel PET biomarker designed to detect malignant breast tumors

Researchers at Thomas Jefferson University in Philadelphia, PA, supported in part by NuView Life Sciences, have published an article in the Journal of Nuclear Medicine reporting preclinical results of a novel PET biomarker designed to selectively detect malignant breast tumors.

30 Oct 2009

Herrick Foundation's $3M grant for cancer research

The Barbara Ann Karmanos Cancer Institute announced today it received a $3 million grant from the Herrick Foundation. The initial gift of $1 million launches The Herrick Foundation Cancer Research Challenge, a special initiative to increase research funding at the Karmanos Cancer Institute over the next four years. The additional commitment of $2 million will be given in match funding.

21 Oct 2009

CMS requested for coverage of two FDG PET scans during the initial treatment

Seven medical imaging groups wrote a joint letter to the Centers for Medicare and Medicaid Services (CMS) to formally request coverage of two fluorodeoxyglucose (FDG) positron emission tomography (PET) scans for a patient during the initial treatment evaluation. Currently, CMS covers only one FDG-PET study during initial treatment-a limitation that the groups believe is contrary to good clinical practice under certain circumstances.

20 Oct 2009

Bioluminescence imaging distinguishes tumor growth in vivo; leads to early treatment of eye cancer

At the moment, doctors rely on biopsy analysis to determine the progression of eye cancer. However, researchers now believe that a new technology, bioluminescence imaging (BLI), will allow doctors to detect tumors earlier and quickly choose a method of treatment that doesn't necessarily involve eye surgery.

14 Oct 2009

Hyper-SAGE with MRI sensitivity, a promising tool for in vivo diagnostics and molecular imaging

A new technique in Magnetic Resonance Imaging dubbed "Hyper-SAGE" has the potential to detect ultra low concentrations of clincal targets, such as lung and other cancers. Development of Hyper-SAGE was led by one of the world's foremost authorities on MRI technology, Alexander Pines, a chemist who holds joint appointments with the Lawrence Berkeley National Laboratory (Berkeley Lab) and the University of California, Berkeley.

12 Oct 2009

Canary Foundation to implement biosensor technologies for early cancer detection

Canary Foundation has committed to being the first organization to implement the breakthrough in biosensor technologies in its research pipeline. The new technology promises to revolutionize the early detection cancer field.

12 Oct 2009

White House honors PET researcher with National Science Award

Joanna Fowler, Ph.D., a major contributor to brain research and a pioneer in molecular imaging, is being recognized by the White House with the National Medal of Science-the highest award for lifetime achievement in science. Eight other researchers will join Fowler to receive the award at a White House ceremony on October 7.

8 Oct 2009

ABT Molecular Imaging secures $9 million through its Series A financing

ABT Molecular Imaging, a medical imaging company developing a production platform to generate unit doses of molecular imaging drugs, announced today it has secured a $9 million round of financing.

7 Oct 2009

SNM's joint session with CMOD on molecular imaging biomarkers in clinical research

SNM is collaborating with the International Partnership for Critical Markers of Disease (CMOD) during CMOD's 7th Annual Biomarkers and Surrogate Endpoints Symposium, Bethesda North Marriott Hotel and Conference Center, Bethesda, Md., Oct. 19th, 2009.

3 Oct 2009